Esperion Therapeutics, Inc. (ESPR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.180.00%
Close 2026-07-13 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ESPR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -57.6% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 6.3% |
Growth built into the price is above our model estimate.
The price assumes 63.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
ESPR — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continuing
Dated 2026-07-13
Notice of Delisting or Failure to Satisfy a Continuing Listing Rule or Standard; Transfer of Listing. In connection with the consummation of the Merger, on July 13, 2026, the Company (i) notified The Nasdaq Stock Market LLC (“Nasdaq”) of the consummation of the Merger and (ii) requested that Nasdaq file with the Securities and Exchange Commission (the “SEC”) a Notification of Removal from Listing and/or Registration on Form 25 to delist and deregister the shares of Common Stock under Section…
Why it matters: The sales of Enbumyst will show if the Corstasis deal works.
Supportive ifEnbumyst achieves annual U.S. net sales of $160 million or more.
Worry ifEnbumyst fails to reach $160 million in annual U.S. net sales.
Why it matters: Hitting this sales target brings a $40 million payment. It shows the product is accepted.
Supportive ifAnnual U.S. net sales of bempedoic acid products exceed $350 million in 2027.
Worry ifSales drop below $300 million, so there is no payment.
Why it matters: Good market performance will support Esperion's purchase of Corstasis. It will help revenue growth.
Supportive ifEnbumyst sees strong sales growth in its first year.
Worry ifSales are weak and do not meet early projections.
Why it matters: Better operating income is important for Esperion's finances. It shows they are getting closer to making money.
Supportive ifOperating income will be positive in Q2 2026.
Worry ifOperating income stays negative or gets worse in Q2 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$32 on $10,000 · ±0.3% | How much price usually moves either way. |
| Bad day | $670 loss on $10,000 · 6.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,319 loss on $10,000 · 53.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The merger will make Esperion a private company. This affects shareholder value and future plans.
Supportive ifThe merger closes in Q3 2026 after getting all approvals.
Worry ifThe merger will not happen if rules or shareholder needs are not met.
Why it matters: Shareholder approval is needed to finish the deal. It affects Esperion's future plans.
Supportive ifOver 75% of shareholders approve the deal.
Worry ifLess than 50% of shareholders approve the deal.
Why it matters: Shareholder approval is key for the merger to move forward. This will impact Esperion's future.
Watch forShareholders support the merger in the scheduled vote.
Also watch forShareholders do not accept the merger proposal. This delays the deal.
Why it matters: Better operating income shows good cost management and financial health. This is key for investor trust.
Supportive ifOperating income is trending up and improving each year.
Worry ifOperating income keeps going down or stays negative.